Antibodies targeting cdh19 for melanoma

An isolated human antibody or antigen binding fragment thereof capable of binding to human cadherin 19 (CDH19) on the surface of a target cell, comprising a VH region comprising CDR-H1, CDR-H2 and CDR-H3 and a VL region comprising CDR-L1, CDR-L2 and CDR-L3 selected from the group consisting of:

• (a) a VH region comprising CDR-H1 as set forth in SEQ ID NO:
• 94, CDR-H2 as set forth in SEQ ID NO:
• 95, CDR-H3 as set forth in SEQ ID NO:
• 96, and a VL region comprising CDR-L1 as set forth in SEQ ID NO:
• 262, CDR-L2 as set forth in SEQ ID NO:
• 263 and CDR-L3 as set forth in SEQ ID NO:
• 264,
• (b) a VH region comprising CDR-H1 as set forth in CDR-H1 as set forth in SEQ ID NO:
• 100, CDR-H2 as set forth in SEQ ID NO:
• 101, CDR-H3 as set forth in SEQ ID NO:
• 102, and a VL region comprising CDR-L1 as set forth in SEQ ID NO:
• 268, CDR-L2 as set forth in SEQ ID NO:
• 269 and CDR-L3 as set forth in SEQ ID NO:
• 270,
• (c) a VH region comprising CDR-H1 as set forth in CDR-H1 as set forth in SEQ ID NO:
• 118, CDR-H2 as set forth in SEQ ID NO:
• 119, CDR-H3 as set forth in SEQ ID NO:
• 120, and a VL region comprising CDR-L1 as set forth in SEQ ID NO:
• 286, CDR-L2 as set forth in SEQ ID NO:
• 287 and CDR-L3 as set forth in SEQ ID NO:
• 288,
• (d) a VH region comprising CDR-H1 as set forth in CDR-H1 as set forth in SEQ ID NO:
• 154, CDR-H2 as set forth in SEQ ID NO:
• 155, CDR-H3 as set forth in SEQ ID NO:
• 156, and a VL region comprising CDR-L1 as set forth in SEQ ID NO:
• 322, CDR-L2 as set forth in SEQ ID NO:
• 323 and CDR-L3 as set forth in SEQ ID NO:
• 324,
• (e) a VH region comprising CDR-H1 as set forth in CDR-H1 as set forth in SEQ ID NO:
• 100, CDR-H2 as set forth in SEQ ID NO:
• 101, CDR-H3 as set forth in SEQ ID NO:
• 912, and a VL region comprising CDR-L1 as set forth in SEQ ID NO:
• 268, CDR-L2 as set forth in SEQ ID NO:
• 269 and CDR-L3 as set forth in SEQ ID NO:
• 270,
• (f) a VH region comprising CDR-H1 as set forth in CDR-H1 as set forth in SEQ ID NO:
• 100, CDR-H2 as set forth in SEQ ID NO:
• 101, CDR-H3 as set forth in SEQ ID NO:
• 913, and a VL region comprising CDR-L1 as set forth in SEQ ID NO:
• 268, CDR-L2 as set forth in SEQ ID NO:
• 269 and CDR-L3 as set forth in SEQ ID NO:
• 270,
• (g) a VH region comprising CDR-H1 as set forth in CDR-H1 as set forth in SEQ ID NO:
• 94, CDR-H2 as set forth in SEQ ID NO:
• 95, CDR-H3 as set forth in SEQ ID NO:
• 910, and a VL region comprising CDR-L1 as set forth in SEQ ID NO:
• 262, CDR-L2 as set forth in SEQ ID NO:
• 263 and CDR-L3 as set forth in SEQ ID NO:
• 264,
• (h) a VH region comprising CDR-H1 as set forth in CDR-H1 as set forth in SEQ ID NO:
• 94, CDR-H2 as set forth in SEQ ID NO:
• 95, CDR-H3 as set forth in SEQ ID NO:
• 911, and a VL region comprising CDR-L1 as set forth in SEQ ID NO:
• 262, CDR-L2 as set forth in SEQ ID NO:
• 263 and CDR-L3 as set forth in SEQ ID NO:
• 264,
• (i) a VH region comprising CDR-H1 as set forth in CDR-H1 as set forth in SEQ ID NO:
• 118, CDR-H2 as set forth in SEQ ID NO:
• 119, CDR-H3 as set forth in SEQ ID NO:
• 120, and a VL region comprising CDR-L1 as set forth in SEQ ID NO:
• 286, CDR-L2 as set forth in SEQ ID NO:
• 287 and CDR-L3 as set forth in SEQ ID NO:
• 288,
• (j) a VH region comprising CDR-H1 as set forth in CDR-H1 as set forth in SEQ ID NO:
• 118, CDR-H2 as set forth in SEQ ID NO:
• 914, CDR-H3 as set forth in SEQ ID NO:
• 120, and a VL region comprising CDR-L1 as set forth in SEQ ID NO:
• 286, CDR-L2 as set forth in SEQ ID NO:
• 287 and CDR-L3 as set forth in SEQ ID NO:
• 288, and
• (k) a VH region comprising CDR-H1 as set forth in CDR-H1 as set forth in SEQ ID NO:
• 154, CDR-H2 as set forth in SEQ ID NO:
• 155, CDR-H3 as set forth in SEQ ID NO:
• 920, and a VL region comprising CDR-L1 as set forth in SEQ ID NO:
• 322, CDR-L2 as set forth in SEQ ID NO:
• 323 and CDR-L3 as set forth in SEQ ID NO:
• 324.